Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading HALO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.28%166.981.2%$750.32m
INCYIncyte Corporation
-0.89%140.031.7%$620.17m
GILDGilead Sciences, Inc.
-0.35%67.591.0%$592.14m
CELGCelgene Corporation
0.15%123.551.0%$512.89m
BIIBBiogen Inc.
0.06%278.041.3%$452.69m
REGNRegeneron Pharmaceuticals, Inc.
-0.11%368.732.1%$317.40m
KITEKite Pharma, Inc.
-0.83%75.7518.8%$208.39m
ALXNAlexion Pharmaceuticals, Inc.
0.15%120.261.6%$206.10m
TSROTESARO, Inc.
0.71%156.8916.1%$178.71m
ESPREsperion Therapeutics, Inc.
0.69%39.2818.7%$165.64m
ILMNIllumina, Inc.
-0.33%167.253.7%$164.71m
AUPHAurinia Pharmaceuticals Inc.
0.41%8.576.3%$149.47m
CLVSClovis Oncology, Inc.
3.89%69.7917.5%$146.95m
VRTXVertex Pharmaceuticals Incorporated
0.23%90.252.2%$135.28m
EXELExelixis, Inc.
0.29%20.547.0%$106.50m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.